canertinib has been researched along with Melanoma in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Berwick, M; Ho, J; Khan, A; Kirkwood, JM; Lee, JY; Ng, YK; Siegfried, JM; Stabile, LP; Supko, KM; Torres, SM | 1 |
Abdiu, A; Djerf Severinsson, EA; Gréen, H; Hallbeck, AL; Stål, O; Trinks, C; Walz, TM | 1 |
2 other study(ies) available for canertinib and Melanoma
Article | Year |
---|---|
Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; Humans; Indoles; Inhibitory Concentration 50; Ligands; Melanoma; Molecular Targeted Therapy; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Signal Transduction; Skin Neoplasms; Sulfonamides; Vemurafenib | 2014 |
The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Female; Humans; Melanoma; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptor, ErbB-3; STAT3 Transcription Factor | 2011 |